Technical Pointers on Biotechnology Equities -- Sarepta Therapeutics, Advaxis, Sequenom, PTC Therapeutics, and Ampio Pharma

Aug 07, 2015, 09:20 ET from

NEW YORK, August 7, 2015 /PRNewswire/ --

Equity Research Institute has initiated coverage on the following equities: Sarepta Therapeutics Inc. (NASDAQ: SRPT), Advaxis Inc. (NASDAQ: ADXS), Sequenom Inc. (NASDAQ: SQNM), PTC Therapeutics Inc. (NASDAQ: PTCT), and Ampio Pharmaceuticals Inc. (AMEX: AMPE). Free research report on Sarepta Therapeutics can be accessed at On Thursday, August 06, 2015, the NASDAQ Composite ended at 5,056.44, down 1.62%, the Dow Jones Industrial Average lost 0.69%, to finish the day at 17,419.75, and the S&P 500 closed at 2,083.56, down 0.78%. The losses were broad based as seven out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.  

Sarepta Therapeutics Inc.'s stock finished Thursday's session 5.81% higher at $34.63. A total of 1.75 million shares were traded, which was above its three months average volume of 1.64 million shares. Over the last one month and the previous three months, Sarepta Therapeutics Inc.'s shares have surged 22.41% and 130.25%, respectively. Additionally, the stock has rallied 139.32% since the beginning of 2015. The company's shares are trading above their 50-day and 200-day moving averages by 15.77% and 87.07%, respectively. Sarepta Therapeutics Inc.'s stock has a Relative Strength Index (RSI) of 66.01. Sign up and read the free notes on SRPT at:

On Thursday, shares in Advaxis Inc. ended the session 12.09% lower at $13.89. The stock reported a trading volume of 1.29 million shares, below its three months average volume of 1.47 million shares. Advaxis Inc.'s shares have declined 19.20% in the last one month and 28.25% in the previous three months. However, the stock has surged 73.41% on YTD basis. The company's shares are trading 6.92% above their 200-day moving average. Moreover, shares of Advaxis Inc. have an RSI of 29.70. The complimentary notes on ADXS can be downloaded in PDF format at:

On Thursday, Sequenom Inc.'s stock plummeted 16.67%, to close the day at $2.35. The stock recorded a trading volume of 4.55 million shares, much above its three months average volume of 1.49 million shares. Over the last one month and over the past three months, Sequenom Inc.'s shares have declined 16.67% and 37.99%, respectively. Furthermore, the stock has lost 36.49% since the start of this year. The company's shares are trading 24.55% below their 50-day moving average. Additionally, Sequenom Inc. traded at a PE ratio of 18.08 and has an RSI of 28.10. Register for free on Equity Research Institute and access the latest research on SQNM at:

On Thursday, shares in PTC Therapeutics Inc. recorded a trading volume of 0.46 million shares, lower than their three months average volume of 0.65 million shares. The stock ended the day 7.45% lower at $45.69. Although, PTC Therapeutics Inc.'s stock has advanced 2.72% in the last one month, it has lost 17.12% in the previous three months and 11.74% on YTD basis. The stock is trading below its 50-day and 200-day moving averages by 12.91% and 17.00%, respectively. Furthermore, shares of PTC Therapeutics Inc. have an RSI of 35.22. The complete research on PTCT is available for free at:

Ampio Pharmaceuticals Inc.'s stock edged 0.81% lower, to close Thursday's session at $2.46. The stock recorded a trading volume of 0.21 million shares, much below its three months average volume of 0.66 million shares. Over the last one month and the previous three months, Ampio Pharmaceuticals Inc.'s shares have advanced 5.13% and 5.58%, respectively. However, the stock has plummeted 28.28% since the start of this year. The company's shares are trading 5.26% and 39.67% below their 50-day and 200-day moving averages, respectively. Furthermore, Ampio Pharmaceuticals Inc.'s stock has an RSI of 43.86. Free in-depth research on AMPE is available at:


About Equity Research Institute: 

Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ERI has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.


ERI, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at)

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.